According to the IMARC Group, the chronic pain market reached a value of USD 21.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 29.9 Billion by 2035, exhibiting a growth rate (CAGR) of 2.90% during 2025-2035. This can be attributed to the rising emphasis on improving medications to simplify treatments and reduce adverse effects, especially for the elderly and pediatric population.

Chronic pain represents long-standing discomfort that lasts beyond the usual recovery period or coexists with a chronic health condition. The chronic pain market is experiencing significant growth driven by the increasing prevalence of such conditions, attributed to aging populations, sedentary lifestyles, and rising rates of obesity and diabetes, thus fueling demand for effective management solutions. Besides this, heightened awareness of the importance of comprehensive management is encouraging more patients to seek medical care, thereby catalyzing the chronic pain market expansion.

Request for a sample of this report: https://www.imarcgroup.com/chronic-pain-market/requestsample

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario

• Historical, current, and future performance of the Chronic Pain Market

• Historical, current, and future performance of various therapeutic categories in the market

• Sales of various drugs across the Chronic Pain Market

• Reimbursement scenario in the market

• In-market and pipeline drugs

This report also provides a detailed analysis of the current Chronic Pain Market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/chronic-pain-market

Competitive Landscape with key players:

The competitive landscape of the Chronic Pain Market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Pfizer

2. Biodelivery Sciences

3. Astrazeneca

4. Purdue Pharma

5. Pfizer

6. Tris Pharma

7. Eli Lilly and Company

8. AstraZeneca

9. Braeburn Pharmaceuticals

10. Vertanical GmbH

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145